Upgrade to SI Premium - Free Trial

Cerus (CERS) Presents Results of European Phase 3 Chronic Anemia Study at EHA

June 15, 2018 11:30 AM
Cerus Corporation (Nasdaq: CERS) announced that results from SPARC, the Company’s European Phase 3 study evaluating the efficacy and safety ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles